+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A new survival model for hyperthermic intraperitoneal chemoperfusion (Hipec) in tumor-bearing rats in the treatment of advanced ovarian cancer



A new survival model for hyperthermic intraperitoneal chemoperfusion (Hipec) in tumor-bearing rats in the treatment of advanced ovarian cancer



European Journal of Cancer 50: S183-S184




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 067138231

Download citation: RISBibTeXText

DOI: 10.1016/s0959-8049(14)50670-3


Related references

A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis. Bmc Cancer 5: 56, 2005

Experimental study of antitumour activity and effects on leukocyte count of intraperitoneal administration and hyperthermic intraperitoneal chemoperfusion (HIPEC) with dioxadet in a rat model of ovarian cancer. Journal of ChemoTherapy 28(3): 203-209, 2017

A new animal model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing mice in the treatment of peritoneal carcinomatosis of ovarian origin. Journal of Visceral Surgery 155(3): 183-189, 2017

Both heat and new chemotherapeutic drug dioxadet in hyperthermic intraperitoneal chemoperfusion improved survival in rat ovarian cancer model. Journal of Surgical Oncology 113(4): 438-442, 2016

A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. Gynecologic Oncology 136(1): 130-135, 2015

Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer. Minerva Ginecologica 69(2): 119-127, 2016

Hyperthermic intraperitoneal chemoperfusion (HIPEC) decrease wound strength of colonic anastomosis in a rat model. International Journal of Colorectal Disease 22(8): 941-947, 2007

Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence. Current Pharmaceutical Design 18(25): 3793-3803, 2012

HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. International Journal of Cancer 136(3): 699-708, 2015

Commment on the review entitled "A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer" by Chiva LM and Gonzalez-Martin A. Gynecologic Oncology Reports 15: 7-8, 2016

Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. British Journal of Surgery 87(8): 1006-1015, 2000

Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. British Journal of Surgery 88(1): 152, 2001

The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis. Journal of Ovarian Research 12(1): 33, 2019

Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. International Journal of Gynecological Cancer 22(5): 778-785, 2012

Extension of recurrence-free and overall survival in patients with ovarian cancer stage III using hyperthermic intraperitoneal chemotherapy (HIPEC). Strahlentherapie und Onkologie 2018, 2018